Page 6 - Yongjun Liu News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Yongjun liu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Yongjun Liu Today - Breaking & Trending Today

UNION, Innovent partner to develop and market orismilast in China

UNION has signed a strategic collaboration and license agreement with Innovent Biologics for the development and commercialisation of orismilast in China. ....

Hong Kong , Innovent Biologics , Yongjun Liu , Kim Kj , Mainland China ,

Innovent and UNION Therapeutics Enter into Strategic Collaboration and License Agreement for Orismilast, a Next-generation PDE4 Inhibitor for Inflammatory Dermatology Conditions

Innovent and UNION Therapeutics Enter into Strategic Collaboration and License Agreement for Orismilast, a Next-generation PDE4 Inhibitor for Inflammatory Dermatology Conditions
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Hong Kong , Adimab Incyte , Yongjun Liu , Kim Kj , Eli Lilly , Prnewswire Innovent Biologics Inc , Md Anderson Cancer Center , Incyte Corporation , Chief Executive Officer , Main Board , Stock Exchange , Hong Kong Limited , Biologics License Application , Cancer Center , Mainland China ,

UNION therapeutics and Innovent Biologics enter into strategic collaboration and license agreement for orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditions

UNION therapeutics and Innovent Biologics enter into strategic collaboration and license agreement for orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditions
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Hong Kong , Adimab Incyte , Yongjun Liu , Kim Kj , Fischer Ravn , Morten Boesen , Eli Lilly , Matthew Cole , Innovent Biologics , Md Anderson Cancer Center , Point Communications , Innovent Biologics Inc , Consilium Strategic Communications , Chief Executive Officer , Main Board , Stock Exchange , Hong Kong Limited , Biologics License Application , Cancer Center , Chief Financial Officer ,

Innovent and GenFleet Announce Exclusive Global License Agreement for GFH925 (KRAS G12C Inhibitor)

Innovent and GenFleet Announce Exclusive Global License Agreement for GFH925 (KRAS G12C Inhibitor)
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Hong Kong , Adimab Incyte , Yongjun Liu , Eli Lilly , Yilong Wu , Prnewswire Innovent Biologics Inc , Md Anderson Cancer Center , Guangdong Lung Cancer Institute , National Medical Products Administration , Shanghai Inc , Incyte Corporation , Innovent Biologics Inc , Genfleet Therapeutics , Investigational New Drug , New Drug Application , Jiong Lan , Main Board , Stock Exchange , Hong Kong Limited , Biologics License Application , Cancer Center , Mainland China ,

Innovent Announces License Agreement with Synaffix in an ADC Technology Deal

Innovent Announces License Agreement with Synaffix in an ADC Technology Deal
News provided by
Share this article
Share this article
SAN FRANCISCO and SUZHOU, China, June 28, 2021 /PRNewswire/ Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced the signing of a non-exclusive, target-specific license agreement with Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class therapeutic index.
Under the terms of the agreement, Synaffix will provide all the necessary proprietary ADC technologies including GlycoConnect™ , HydraSpace™ and one of its toxSYN™ linker-payloads, to enable Innovent to rapidly progress one of its antibodies as a best-in-class ADC ....

United States , Hong Kong , Innovent Biologics , Adimab Incyte , Yongjun Liu , Eli Lilly , National Reimbursement Drug List , Md Anderson Cancer Center , Innovent Biologics Inc , Main Board , Stock Exchange , Hong Kong Limited , Biologics License Application , Cancer Center , Mersana Therapeutics , Biogeneration Ventures , ஒன்றுபட்டது மாநிலங்களில் , ஹாங் காங் , எலி லில்லி , தேசிய கொடுக்கப்படுவதுடன் மருந்து பட்டியல் , ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் , பிரதான பலகை , ஸ்டாக் பரிமாற்றம் , ஹாங் காங் வரையறுக்கப்பட்டவை , உயிரியல் உரிமம் விண்ணப்பம் , புற்றுநோய் மையம் ,